Indivior, leader in opioid treatment, trades near 52-week lows. Read more on INDV stock's financials, growth challenges, and ...

Tardive Dyskinesia TD as a neurological disorder resulting in involuntary repetitive movement disorder as a disease of brain ...

Return on Assets (ROA): Neurocrine Biosciences's financial strength is reflected in its exceptional ROA, which exceeds ...

Going off antipsychotics can feel like proving something, as well as resolving issues of antipsychotic use. But hear me out ...

Some studies suggest that certain herbal or dietary supplements may help reduce symptoms of tardive dyskinesia. If tardive dyskinesia is disrupting your life, your doctor will adjust your ...

THURSDAY, March 20, 2025 (HealthDay News) — Disruptions in amino acid and lipid metabolism may be biomarkers of tardive dyskinesia (TD), according to a study published online Feb. 21 in Schizophrenia ...

Neurocrine Biosciences’ Kinect 4 open-label study (NCT02405091) found that 59.2% of patients achieved remission of tardive dyskinesia through once-daily doses of Ingrezza (valbenazine). Post-hoc ...

Neurocrine Biosciences’ Kinect 4 open-label study (NCT02405091) found that 59.2% of patients achieved remission of tardive dyskinesia through once-daily doses of Ingrezza (valbenazine).

Neurocrine (NBIX) presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the ...